We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.
GlaxoSmithKline’s (GSK) interleukin-5 (IL-5) inhibitor has received approval from the US Food and Drug Administration (FDA) for the treatment of chronic rhinosinusitis with nasal polyps (CRSwNP).
GlaxoSmithKline (GSK) has dosed the first patient in a Phase III trial investigating its long-acting anti-IL-5 monoclonal antibody for the treatment of severe eosinophilic asthma (SEA).